[{"id":"ba46c2a2-b8a0-4d55-8e36-8db640687fe6","acronym":"HER2","url":"https://clinicaltrials.gov/study/NCT05650879","created_at":"2022-12-14T14:58:21.956Z","updated_at":"2024-07-02T16:34:37.125Z","phase":"Phase 1","brief_title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05650879 - HER2","lead_sponsor":"Enliven Therapeutics","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-07"}]